In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

AbbVie recently signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. In 2013, AbbVie (NYSE: ABBV) became a publicly ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...

AbbVie is a Dividend King with solid growth prospects. Enbridge is a leading pipeline operator and natural gas utility with ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy ...